



IFW

Docket No.: 1422-0714PUS1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Masazumi YASUMOTO et al.

Application No.: 10/574,904

Confirmation No.: N/A

Filed: April 6, 2006

Art Unit: N/A

For: COMPOSITION FOR INHIBITING
FUNCTION OF HUMAN FLT3

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT

(SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE FINAL
REJECTION OR NOTICE OF ALLOWANCE OR CONCURRENTLY WITH A RULE
1.114 RCE APPLICATION)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-SB08(s), attached hereto.

II. COPIES

a. Copies of cited U.S. patents and patent application publications are not included.
Copies of foreign patent documents and non-patent literature are included.

67

b. Some or all of the documents listed on the PTO-SB08 are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.

c. REFERENCES PREVIOUSLY CITED OR SUBMITTED - Pursuant to 37 C.F.R. §1.98(d), consideration of information listed on the PTO-SB08 form(s) is requested since any patents, publications, or other information which are listed on the PTO-SB08 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

III. CONCISE EXPLANATION OF THE RELEVANCE

(check at least one box)

a. DOCUMENTS IN THE ENGLISH LANGUAGE - The patents, publications, or other information listed on the attached PTO SB08 are in the English language and therefore, do not require a statement of relevancy.

b. DOCUMENTS NOT IN THE ENGLISH LANGUAGE - A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

c. ENGLISH LANGUAGE SEARCH REPORT - An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3).

d. OTHER - The following additional information is provided for the Examiner's consideration.

IV. FEES (check one box)

- a. This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.
- b. This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.
- c. This Information Disclosure Statement is being filed within three months of the filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required.
(This section is not to be used with RCE's.)
- d. This Information Disclosure Statement is being filed within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required.
- e. This Information Disclosure Statement is being filed concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.
- f. This Information Disclosure Statement is being filed before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account for the fee as required by 37 C.F.R. § 1.17(p).
- g. This Information Disclosure Statement is being filed before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)).

No statement; therefore, a fee as required by 37 C.F.R. § 1.17(p) is attached.

or

See the statement below. No fee is required.

V. STATEMENT UNDER 37 C.F.R. § 1.97(e)(check only one box)

The undersigned hereby states that:

- a. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this IDS; or
- b. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- c. No item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS.
- d. Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

VI. PAYMENT OF FEES (check one box)

- The required fee is listed on the attached Fee Transmittal.


No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated:

Respectfully submitted,

By  #4125874
Marc S. Weiner
Registration No.: 32,181
BIRCH, STEWART, KOLASCH & BIRCH, LLP
8110 Gatehouse Road
Suite 100 East
P.O. Box 747
Falls Church, Virginia 22040-0747
(703) 205-8000
Attorney for Applicant

Attachment(s):

- PTO-SB08
- Documents
- Foreign Search Report
- Fee
- Other:



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

Complete if Known

Application Number	10/574,904		
Filing Date	April 6, 2006		
First Named Inventor	Masazumi YASUMOTO		
Art Unit	N/A		
Examiner Name	Not Yet Assigned		
Sheet	1	of	1
		Attorney Docket Number	1422-0714PUS1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	²
CA		HOLT et al., Molecular and Cellular Biology, Feb. 1988, p. 963-973	
CB		BETTINGER et al., Current Opinion in Molecular Therapeutics, 2001, 3(2), pages 116-124.	
CC		VERZELETTI et al., Human Gene Therapy, October 10, 1998, Vol. 9, Pages 2243-2251	
CD		WIERDA et al., Seminars in Oncology, October 2000, Vol 27, No 5, Pages 502-511	
CE		GEWIRTZ et al., Blood, August 1, 1998, Vol 92, No. 3, pages 712-736.	
CF		BERNSTEIN et al., Nature, January 18, 2001, Vol. 409 pages 363-366.	
CG		TUSCHL et al., Genes & Dev. 1999, Vol. 13 pages 3191-3197.	
CH		ZAMORE et al., Cell, March 31, 2000, Vol. 101, pages 25-33.	
CI		NYKANEN et al., Cell, November 2, 2001, Vol. 107, pages 309-321.	
CJ		ELBASHIR et al., Genes & Dev. 2001, Vol. 15, pages 188-200.	
CK		LIPARDI et al., Cell, November 2, 2001, Vol. 107 pages 297-307.	
CL		CAPLEN et al., PNAS, August 14, 2001, Vol. 98, No. 17, pages 9742-9747.	
CM		DREXLER et al., Leukemia, 1996, Vol. 10, pages 588-599.	
CN		NAKAO et al., Leukemia, 1996, Vol 10, pages 1911-1918.	
CO		YOKOTA et al., Leukemia, 1997, Vol 11, pages 1605-1609.	
CP		KIYOI et al., Leukemia, 1997, Vol. 11, pages 1447-1452.	
CQ		GILLILAND et al., Blood, September 1, 2002, Vol. 100, No. 5, page 1532- 1542.	
CR		LEVIS et al., Blood, June 1, 2002, Vol. 99, No. 11, pages 3885-3891.	
CS		O'FARRELL et al., Blood, May 1, 2003, Vol. 101, No. 9, pages 3597-3605.	
CT		GILES et al., Blood, August 1, 2003, Vol. 102, No. 3, Pages 795-801.	
CU		LEVIS et al., Blood, August 1, 2001, Vol. 98, No. 3, pages 885-887.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	1422-0714PUS1
-------	---	----	---	------------------------	---------------

Complete if Known

Application Number	10/574,904
--------------------	------------

Filing Date	April 6, 2006
-------------	---------------

First Named Inventor	Masazumi YASUMOTO
----------------------	-------------------

Art Unit	N/A
----------	-----

Examiner Name	Not Yet Assigned
---------------	------------------

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	BA**	WO-2000/11470-A1	03-02-2000		T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	CA**	ROSNET, O. et al., Blood, August 15, 1993, 82(4), pages 1110-1119.			
	CB**	YEE et al., Blood, October 15, 2002, 100(8), pages 2941-9.			
	CC**	YAMAMOTO et al., Blood, April 15, 2001, 97(8), pages 2434-9.			
	CD**	FIRE et al., Nature, February 19, 1998, Vol. 391, pages 806-811.			
	CE**	DYKXHOORN et al., Nature Rev. Mol. Cell Biol., June 2003, Vol. 4, pages 457-467.			
	CF**	ELBASHIR et al., Nature, May 24, 2001, Vol. 411, pages 494-498.			
	CG**	HEIDENREICH et al., Blood, April 15, 2003, 101(8), pages 3157-3163.			
	CH**	MARTINEZ et al., Proc. Natl. Acad. Sci. USA, November 12, 2002, Vol. 99, pages 14849-14854.			
	CI**	WILDA et al., Oncogene, 2002, Vol. 21, pages 5716-5724.			
	CJ**	SCHERR et al., Blood, February 15, 2003, 101(4), pages 1566-1569.			
	CK**	WOHLBOLD et al., Blood, September 15, 2003, 102(6), pages 2236-2239.			
	CL**	SHEN et al., FEBS Letters, March 27, 2002, Vol. 539, pages 111-114.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------

MSW/clb